Stress Management Intervention for Living With Epilepsy (SMILE) (SMILE)
Primary Purpose
Epilepsy
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Progressive muscle relaxation
Sham exercise
Sponsored by
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring Epilepsy, seizures, stress reduction
Eligibility Criteria
Inclusion Criteria:
- Age 18 years and above
- English speaking
- Partial epilepsy consistent with ILAE criteria supported by either EEG or MRI data
- Experiencing at least 2 seizures/month
- Reported awareness of all seizures, including seizures in a cluster
One of the following:
- Patient-reported ability to self-predict seizures
- Patient-reported awareness of trigger factors, including stress
- Patient-reported awareness of premonitory features
- Able to maintain accurate e-diary independently
- Minimum 6th grade reading level as screened by WRAT administration
- Must be on a stable dose of anti-epileptic drugs for at least 30 days prior to study entry
- May be on stable dose of SSRI, SNRI, or atypical antipsychotic for at least 6 months
- May be on a stable dose of benzodiazepines (if so, dose stable for at least 30 days prior to study entry)
For inclusion in clinical trial phase, patient must be/have:
- A minimum of 4 seizures documented in the 8-week baseline phase (or 6 seizures in the 12-week extended baseline phase)
- At least 1 seizure per 4-week period in two of the three 4-week periods in the extended baseline phase
- Diaries satisfactorily completed during baseline phase
- Complied with study requirements during the baseline phase
Exclusion Criteria:
- Non-motor simple partial seizures only
- Concurrent VNS use
- History of suicide attempt within the past 2 years
- Current suicidality
- Not competent to sign consent
- Status epilepticus within the previous 6 months
- Began regularly using behavioral techniques for stress reduction within past 3 months
- Did not benefit from an adequate trial of a valid stress reduction technique
- Progressive neurologic condition that the investigator believes would affect seizure frequency
- Any history of substance abuse within the previous 2 years
- History of poor medication compliance as judged by the investigator
- Psychiatric illness that requires change in medication dose
- Any medical or psychiatric condition that would impair reliable participation in the trial
- Intermittent use of benzodiazepines (if used for sleep, will be determined case by case)
Sites / Locations
- University of California San Francisco
- Montefiore Medical Center
- University of Cincinnati
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Progressive muscle relaxation
Sham exercise
Arm Description
Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
Subjects practice a sham exercise consisting of focused attention activities
Outcomes
Primary Outcome Measures
Change in seizure frequency
Secondary Outcome Measures
Full Information
NCT ID
NCT01444183
First Posted
September 15, 2011
Last Updated
April 17, 2018
Sponsor
Montefiore Medical Center
Collaborators
Charles L Shor Foundation for Epilepsy Research, University of Cincinnati
1. Study Identification
Unique Protocol Identification Number
NCT01444183
Brief Title
Stress Management Intervention for Living With Epilepsy (SMILE)
Acronym
SMILE
Official Title
Pre-emptive Treatment in Epilepsy Using Electronic Diaries: Towards a New Frontier in Epilepsy Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Montefiore Medical Center
Collaborators
Charles L Shor Foundation for Epilepsy Research, University of Cincinnati
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The study will examine whether a stress reduction intervention reduces the number of seizures in people with drug resistant epilepsy.
Detailed Description
The study will examine whether a stress reduction intervention reduces the number of seizures in people with drug resistant epilepsy. In the proposed randomized controlled, double blind trial, the investigators will enroll subjects with frequent seizures, especially those who identify stress as a seizure precipitant. There is an observational phase (8-12 weeks) and a treatment phase (12 weeks). During the observational phase, subjects will be monitored multiple times daily via smart phone devices, in order to identify high risk days for seizures. In the treatment phase, subjects will be randomly assigned to one of two groups receiving different focused attention practices. These behavioral interventions will be administered daily with extra interventions applied on days of higher risk.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
Epilepsy, seizures, stress reduction
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
95 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Progressive muscle relaxation
Arm Type
Active Comparator
Arm Description
Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
Arm Title
Sham exercise
Arm Type
Sham Comparator
Arm Description
Subjects practice a sham exercise consisting of focused attention activities
Intervention Type
Behavioral
Intervention Name(s)
Progressive muscle relaxation
Intervention Description
Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
Intervention Type
Behavioral
Intervention Name(s)
Sham exercise
Intervention Description
The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
Primary Outcome Measure Information:
Title
Change in seizure frequency
Time Frame
End of baseline and end of 12 week clinical trial
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 years and above
English speaking
Partial epilepsy consistent with ILAE criteria supported by either EEG or MRI data
Experiencing at least 2 seizures/month
Reported awareness of all seizures, including seizures in a cluster
One of the following:
Patient-reported ability to self-predict seizures
Patient-reported awareness of trigger factors, including stress
Patient-reported awareness of premonitory features
Able to maintain accurate e-diary independently
Minimum 6th grade reading level as screened by WRAT administration
Must be on a stable dose of anti-epileptic drugs for at least 30 days prior to study entry
May be on stable dose of SSRI, SNRI, or atypical antipsychotic for at least 6 months
May be on a stable dose of benzodiazepines (if so, dose stable for at least 30 days prior to study entry)
For inclusion in clinical trial phase, patient must be/have:
A minimum of 4 seizures documented in the 8-week baseline phase (or 6 seizures in the 12-week extended baseline phase)
At least 1 seizure per 4-week period in two of the three 4-week periods in the extended baseline phase
Diaries satisfactorily completed during baseline phase
Complied with study requirements during the baseline phase
Exclusion Criteria:
Non-motor simple partial seizures only
Concurrent VNS use
History of suicide attempt within the past 2 years
Current suicidality
Not competent to sign consent
Status epilepticus within the previous 6 months
Began regularly using behavioral techniques for stress reduction within past 3 months
Did not benefit from an adequate trial of a valid stress reduction technique
Progressive neurologic condition that the investigator believes would affect seizure frequency
Any history of substance abuse within the previous 2 years
History of poor medication compliance as judged by the investigator
Psychiatric illness that requires change in medication dose
Any medical or psychiatric condition that would impair reliable participation in the trial
Intermittent use of benzodiazepines (if used for sleep, will be determined case by case)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sheryl Haut, MD
Organizational Affiliation
Montefiore Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Privitera, MD
Organizational Affiliation
University of Cincinnati
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Susannah Cornes, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
19138755
Citation
Hall CB, Lipton RB, Tennen H, Haut SR. Early follow-up data from seizure diaries can be used to predict subsequent seizures in same cohort by borrowing strength across participants. Epilepsy Behav. 2009 Mar;14(3):472-5. doi: 10.1016/j.yebeh.2008.12.011. Epub 2009 Jan 10.
Results Reference
background
PubMed Identifier
17998482
Citation
Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology. 2007 Nov 13;69(20):1905-10. doi: 10.1212/01.wnl.0000278112.48285.84.
Results Reference
background
PubMed Identifier
19646331
Citation
Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol. 2010 Feb;15(Pt 1):1-39. doi: 10.1348/135910709X466063. Epub 2009 Jul 28.
Results Reference
background
PubMed Identifier
16310021
Citation
Nickel C, Kettler C, Muehlbacher M, Lahmann C, Tritt K, Fartacek R, Bachler E, Rother N, Egger C, Rother WK, Loew TH, Nickel MK. Effect of progressive muscle relaxation in adolescent female bronchial asthma patients: a randomized, double-blind, controlled study. J Psychosom Res. 2005 Dec;59(6):393-8. doi: 10.1016/j.jpsychores.2005.04.008.
Results Reference
background
PubMed Identifier
31645468
Citation
Privitera M, Haut SR, Lipton RB, McGinley JS, Cornes S. Seizure self-prediction in a randomized controlled trial of stress management. Neurology. 2019 Nov 26;93(22):e2021-e2031. doi: 10.1212/WNL.0000000000008539. Epub 2019 Oct 23.
Results Reference
derived
PubMed Identifier
29444968
Citation
Haut SR, Lipton RB, Cornes S, Dwivedi AK, Wasson R, Cotton S, Strawn JR, Privitera M. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. Neurology. 2018 Mar 13;90(11):e963-e970. doi: 10.1212/WNL.0000000000005109. Epub 2018 Feb 14.
Results Reference
derived
Learn more about this trial
Stress Management Intervention for Living With Epilepsy (SMILE)
We'll reach out to this number within 24 hrs